Atelerix Life Sciences

Peter Barton Hutt Joins Atelerix Life Sciences Board of Directors

Distinguished Counsel and FDA Regulatory Scholar Will Lend His Expertise on Corporate and Strategic Matters

His extensive experience and knowledge of life sciences, including expertise around opioids in our healthcare system, will be real assets as we pioneer a new approach to the opioid crisis.”

— David Kalergis, CEO of Atelerix Life Sciences Inc.CHARLOTTESVILLE, VA, UNITED STATES, November 22, 2021 / — Atelerix Life Sciences Inc., a leader in new therapeutics for unmet medical needs related to opioid use, today announced that Peter Barton Hutt has joined its Board of Directors effective immediately. An expert in Food and Drug Law, Mr. Hutt is Senior Counsel in the Washington, DC, office of Covington & Burling LLP. Mr. Hutt has been with the firm since 1960, excluding his four-year tenure as Chief Counsel for the Food and Drug Administration.